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The hepatitis delta virus (HDV) is distributed worldwide and related to the most severe form of viral hepatitis. HDV is a satellite
RNA virus dependent on hepatitis B surface antigens to assemble its envelope and thus form new virions and propagate infection.
HDV has a small 1.7 Kb genome making it the smallest known human virus. This deceivingly simple virus has unique biological
features andmany aspects of its life cycle remain elusive.The present review endeavors to gather the available information on HDV
epidemiology and clinical features as well as HDV biology.
1. Introduction
In 1977, a novel antigen was found in the nucleus of hepato-
cytes from patients with a more severe form of hepatitis B.
It was first thought to be a previously unknown marker of
hepatitis B virus (HBV). Only later, it was found that the then
called delta antigen was not part of HBV but of a separate
defective virus that requires the presence of HBV for infec-
tion. The newfound virus was designated hepatitis delta
virus (HDV) and, by 1986, its RNA genome was cloned and
sequenced (reviewed by [1]). This peculiar virus has been
classified as the only member of the genus Deltavirus due to
its uniqueness [2]. The HDV virion is a hybrid particle,
composed of the delta antigen and HDV RNA enclosed by
the surface antigens of HBV (HBsAgs). HDV has the smallest
RNA genome of all known animal viruses. However, it is
comparable, although larger, to viroid RNAs, pathogenic
agents of higher plants.
2. Epidemiology
HDV infection is distributed worldwide, although not uni-
formly, and it is estimated that 5% of HBsAgs carriers are
also infected with HDV, which signifies that there might be
between 15 and 20millionHDV-infected individuals [3].This
is a very rough number because it lacks data from areas where
HBV is highly prevalent and HDV is poorly studied.
HDV is highly endemic in Mediterranean countries, the
Middle East, northern parts of South America, and Central
Africa [4]. HDV also has high prevalence in Turkey [5],
Central Asia [6], and theAmazonian region ofWestern Brazil
[7].
In Southern Europe, HDV infection has been highly
prevalent, with studies from the 1980s and 1990s showing that
the incidence of HDV in HBsAgs positive individuals was
higher than 20% [8].With the implementation of HBV vacci-
nation programs in the 1980s, HDV prevalence considerably
decreased to 5–10% by the late 1990s [9]. However, in the
beginning of the XXI century, the number of HDV-infected
HBsAgs carriers in Europe increased to 8–12% [9, 10]. This
increase has been attributed to immigration of individuals
from highly endemic regions [10]. Another report claims that
the increase inHDV incidence is not only due to immigration
but also due to other factors associated with HDV modes of
transmission [9]. Drug addiction and other risk behaviors,
such as multiple sexual partners, tattooing and piercing,
or uncontrolled medical procedures, have been shown to
contribute to the spread of hepatitis D in Italy [9]. In fact, in
western countries, the virus is highly prevalent in intravenous
drug addicts with chronic HBV infection [9, 10].
More recent and reliable data are needed, especially from
poorly studied regions. As an example, only recently are data
starting to emerge from the United States of America. A 2013
survey has shown that in Northern California, 8% of 499
chronic HBV patients tested positive for HDV infection [11].
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Based on nucleotide sequence analysis, eight HDV geno-
types have been defined, some of which are distributed
by distinct geographic regions [4, 12]. The divergence in
nucleotide sequence between isolates of the same genotype
is less than 15% and between different genotypes it can be as
high as 40% [4]. HDV genotype 1 is the most common and
prevalent worldwide, present mainly in Europe, Middle East,
North America, and Northern Africa. It is associated with
both severe and mild forms of the disease [13]. Genotype 2
is more common in the Far East, present in Japan, Taiwan,
and parts of Russia [14]. Genotype 2 is associated with a
milder disease course [13]. HDV genotype 3 is exclusively
found in the Amazon Basin [7] and has been associated with
the most aggressive forms of HDV infection. The combined
infection of HDV genotype 3 and HBV genotype F was
associated with fulminant hepatitis in South America [15].
Genotype 4, present in Japan and Taiwan [16], has variable
pathogenicity. A genotype 4 isolate fromOkinawa, Japan, has
been associated with greater progression to cirrhosis than the
genotype 4 predominant in Taiwan [17]. Genotypes 5 to 8
were found inAfrican patientswhohadmigrated toNorthern
Europe [4, 12]. Phylogenetic reconstructions based on the
delta antigen coding sequence have shown a probable ancient
radiation of African lineages [4].
3. Clinical Expression
Hepatitis delta virus is usually associated with a severe form
of hepatitis, but the range of clinical manifestations is very
wide going from asymptomatic cases to fulminant hepatitis.
Regarding HDV transmission, like its helper virus HBV,
it is parenterally transmitted through exposure to infected
blood or body fluids. Intrafamilial spread is naturally com-
mon in highly endemic regions.
HDV requires the presence of HBsAgs to form new infec-
tious virions and propagate HDV infection.Thus, hepatitis D
only occurs in individuals infected with HBV. Consequently,
there are two major patterns of infection: “coinfection”
with HBV and HDV or “superinfection” of patients already
infected with HBV. A rare third pattern has been reported; it
can occur after liver transplantation for an HDV-infected
individual and is designated as “helper-independent latent
infection” [18]. In this scenario, an initial HDV infection of
the new liver occurs without any apparent help from HBV.
Such an infection remains asymptomatic unless reactivated
by HBV appearance [18].
For an HBV and HDV acute coinfection, the most com-
mon outcome (95%) is viral clearance [14]. However, it can
be more severe than an acute HBV monoinfection, resulting
in some cases in acute liver failure [19]. Acute hepatitis strikes
after an incubation period of 3–7 weeks, beginning with a
period of nonspecific symptoms such as fatigue, lethargy, or
nausea [20].
HDV superinfection of chronic HBV patients also causes
severe acute hepatitis, but in this case, for up to 80% of
patients, it progresses to chronicity [21].The processes, which
determine whether a patient clears HDV spontaneously or
becomes chronically infected, remain unclear. When chronic
HDV infection is established, the preexisting liver disease
caused by HBV is usually aggravated [22]. It has been
claimed that, during the acute phase of HDV infection, HBV
replication is suppressed to very low levels and that this sup-
pression can persist once a chronic HDV infection is estab-
lished [23]. Patients with HDV superinfection suffer a more
rapid progression to cirrhosis [24, 25], increased liver decom-
pensation, and eventually death [26], when compared with
patients with HBV monoinfection. Despite the higher rates
of progression to cirrhosis, not all published studies refer
to an increased rate of hepatocellular carcinoma [27]. One
explanation of this may be the abovementioned suppression
of HBV replication by HDV, since other studies assert that
higher HBV DNA serum levels correlate with a greater risk
of carcinoma [28].
4. Diagnosis
Since HDV is a satellite virus of HBV, every HBsAgs positive
patient should be screened for coinfection with HDV; that is,
patients should be tested, at least once, for anti-HDVantibod-
ies. A negative result does not justify testing for HDV RNA
as, so far, it seems that every individual infected with HDV
develops anti-HDV antibodies [29]. In contrast, a positive
result for anti-HDV antibodies requires confirmation of con-
tinued HDV infection, through detection of HDV RNA in
serum. Anti-HDV antibodiesmay be present even after HDV
RNA has disappeared during recovery from the infection
[29].
Currently, there is no need for quantification of the HDV
RNA levels in serum during the diagnosis step. There is no
evidence that a correlation exists between the stage of liver
disease and the levels of HDV RNA [30]. Thus, a liver biopsy
is still the major tool for evaluating the stage of delta hepatitis
in patients [29]. However, a quantitative assay of HDV RNA
is useful during the therapy stage to monitor the treatment
response of patients undergoing therapy. Unfortunately, very
few data are available on the levels of HDV RNA during the
different stages of the disease. Thus, there is no accepted
threshold level at which one might recommend treatment.
For some time, quantification of HDV RNA levels in
clinical samples has suffered from the lack of a standardized
test. Quantification of HDV RNA was done in specialized
laboratories using in-house protocols, which unfortunately
become irrelevant outside the laboratory of origin. Such
assays typically lacked an internal control and were limited
to only one genotype. Furthermore, there is no international
reference standard tomake results from different laboratories
comparable. As proposed elsewhere, an HDV RNA reference
preparation should be defined by the World Health Organi-
zation to be used as an international standard [31].
In 2012, two standard protocols were proposed to detect
and quantify HDV RNA from clinical samples [32, 33]. One
method is described as able to be automated to accurately
quantify the major HDV genotypes present in Europe (geno-
type 1 and the migrant African strains 5–8; [32]). The other
standardized test is described as being able to detect and
quantify all HDV genotypes [33]. Both protocols use a
commercial kit to extract nucleic acids from samples and
include an internal control to enablemonitoring of the overall
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performances of the assay.The one-step RT-qPCRmakes use
of another commercial kit [32, 33].
Application of standardized procedures is crucial to
improve our understanding of HDV RNA kinetics during
the course of disease. It will improve patient management, as
data can be gathered which will help in the decision to start
treatment, as well as monitoring the response to therapy in
chronic patients. Also it will contribute to the screening of
HDV infections in the endemic areas, providingmore reliable
epidemiological data. Overall, acceptance of standardization
will help clarify the pathophysiology of HDV infections.
5. Treatment
Ideally, a successful treatment of anHDV infection eradicates
HDV and its helper virusHBV. Clearance ofHDV is obtained
when both HDV RNA and HDAg in the liver become per-
sistently undetectable and a complete resolution is achieved
when HBsAgs clearance is also obtained.
However, at this time, there is no efficient therapy.
Prolonged treatmentwith recombinant interferons is the only
therapy that has shown antiviral activity against HDV. Such
therapies, which last up to 2 years, have been reported as only
20–40% efficient [34].
In general, when searching for a treatment for viral
disorders, the first and preferred targets analyzed are the viral
components, such as enzymes involved in the virus replica-
tion cycle. But HDV lacks any specific enzymatic function
to target. Since the only known enzymatic activity the virus
possesses is a ribozyme, the virus relies on the host cell to
provide for all other enzymatic activities needed for its life
cycle. This represents a serious challenge in finding an HDV-
specific therapeutic target.
Puzzlingly, the nucleoside and nucleotide analogues used
for treatment of HBV infection are inefficient against HDV.
Although they blockHBVDNA synthesis in chronic patients,
they have little impact on HDV and do not even enhance
interferon treatments [34]. Famciclovir, lamivudine, and ade-
fovir, all used in HBV treatment, have been shown to lack any
significant antiviral activity against HDV [35–37]. Ribavirin,
a nucleotide analogue, which inhibits HDV replication in
cell culture, when administered alone or in combination with
interferon, also failed to increase rates ofHDVRNAclearance
[38].
Interferon-𝛼 (IFN-𝛼) has been used for treatment ofHDV
infections since themid-1980s [39]. Several trials were carried
out exploring different doses and durations. Responses to
treatment varied and clearance occurred at different times
from the beginning of treatment, occurring even after discon-
tinuation of treatment [35]. Researchers have yet to identify
pretreatment characteristics that determine responders and
nonresponders to IFN-𝛼 therapy. It seems that 2 years of treat-
ment with IFN-𝛼 is superior to shorter treatment durations to
obtain HDV RNA clearance [35]. It has been reported that in
a 1-year treatment, there is only a 10 to 20% chance of HDV
clearance, and in a 2-year treatment trial, 20% of patients
were cleared [40]. The rate of response is proportional to the
dose of IFN-𝛼; patients treated with doses of 9 million units
responded better than those treated with only 3million units,
and relapse was common when the IFN-𝛼 dose was reduced
[35]. Unfortunately, a prolonged treatment with high doses
of IFN-𝛼 is tolerated by only a minority of patients [29]. IFN-
𝛼 side effects include flu-like symptoms, fatigue, and weight
loss as well as severe psychiatric disturbances. Patients have a
tendency to becomedeeply depressed; suicides and attempted
suicides have been reported [35]. The severity of reactions
tends to be proportional to IFN-𝛼 dose, and intermittent use
of IFN-𝛼, observed in drug abusers, increased incidence and
severity of side effects [35].
By 2006, IFN-𝛼 was largely replaced by longer-lasting
pegylated IFN-𝛼 (PEG-IFN-𝛼) [38, 41, 42]. Clearance ofHDV
RNAwas obtained for 6 out of 14 patients in a 1-year treatment
plan [41]. However, in a similar study, only 2 patients in
12 were cured [42]. In a third study, 8 patients out of 38
became HDV RNA negative after 72 weeks of treatment [38].
Ribavirin was also used in this trial but without any apparent
beneficial effect [38].
The Hep-Net International hepatitis D intervention trial,
which included 90 patients from Germany, Greece, and
Turkey, tested PEG-IFN-𝛼2a alone or with adefovir and
adefovir alone [36]. HDV RNA clearance was only observed
in patients who had received treatment including PEG-IFN-
𝛼2a, showing an antiviral efficacy in more than 40% of
patients, and 25% became HDV RNA negative [36]. Adefovir
showed little efficacy in reducing HDV RNA levels, but a
PEG-IFN-𝛼2a plus adefovir therapy was superior in reducing
HBsAgs serum levels [36].
Currently, it is usually recommended to treat chronic
hepatitis D with PEG-IFN-𝛼 for one year or longer, if the
patient can tolerate the adverse effects of such therapy [14].
For patients with advanced liver disease, liver transplantation
is the only therapy available [40].
An optimization of the available treatment strategies is
clearly needed, either regarding doses or duration, and also
possible combinations such as PEG-IFN-𝛼2a with adefovir
to also tackle HBsAgs, crucial for HDV propagation. Most
importantly, alternative treatments need to be explored, as
the efficacy of the current therapies is clearly unsatisfactory.
One of the most promising alternatives is the prenylation
inhibitors since, as will be discussed subsequently, prenyla-
tion of HDAg is essential for interaction with HBsAgs. Fur-
thermore, prenylation inhibitors have already been developed
to treat a number of malignancies and were shown to be safe
[43].
6. HDV Biology
6.1. HDV Virions and Putative Host Cell Receptors. An infec-
tious HDV virion is an enveloped, roughly spherical particle,
of around 36 nm in diameter [44].The outer coat of the virion
containing host lipids and the HBsAgs surrounds an inner
nucleocapsid consisting of viral ribonucleoproteins (RNPs)
with the genomic RNA and about 200 molecules of HDAg
per genome [45].
Since HDV andHBV share the same envelope proteins, it
is often assumed that attachment and cell entry occur via
similar mechanisms.
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Several studies have attempted to identify the regions of
the HBsAgs required for HDV and HBV entry. The preS1
region of L-HBsAg is myristoylated at the N-terminus. This
posttranslational modification and about 48 adjacent amino
acids are essential for HBV and HDV entry into hepato-
cytes. Synthetic peptides that mimic this region are potent
inhibitors of virus entry [46].
Many studies have aimed to discover the host receptors
for HBV (and maybe HDV). Many candidates have been
proposed but not confirmed [47].
It has been suggested that functional purinergic receptors
are required forHDV entry as compounds that block the acti-
vation of such receptors inhibitedHDV andHBV infection of
primary human hepatocytes [48]. However, a different study
has since reported that such blocking compounds interfere in
HDV and HBV infection due to their charge and not because
the receptors are directly involved in the process [49]. In fact,
one of the blocking compounds used, ivermectin, reduced
HDV infection when added after virus inoculation just as
well as when added before inoculation [49].This suggests that
ivermectin focuses on a step of the HDV replication cycle
other than the receptor binding stage. In this study, it has
also been shown that HDV cell entry depends on binding to
the glycosaminoglycan side chains of the hepatocyte heparan
sulfate proteoglycans, much like what has been observed for
HBV infection [49].
In contrast to all previous studies, an important new
report by Yan and colleagues demonstrates that a necessary
and sufficient receptor for HBV and HDV is the sodium
taurocholate cotransporting polypeptide [50]. This protein is
a multiple transmembrane transporter expressed in the liver.
Silencing expression of this protein in primary hepatocytes
using small interfering RNAs inhibited HBV and HDV
infection. Expression of this protein in human liver cell lines
rendered them susceptible to infection by HBV and HDV.
Therefore, it is now possible for the first time to study the
infection processes for these viruses in vitro, using established
human liver cell lines, which are much more convenient and
reproducible than primary hepatocyte cultures.
6.2. HDVRNAs. HDVhas a small circular RNAgenomewith
only ∼1700 nucleotides; this sequence length varies by no
more than 30 nucleotides among HDV isolates [51]. In native
conditions, the RNA folds into an unbranched rod-like struc-
ture due to intramolecular base pairing involving around 74%
of its nucleotides [52].
HDV contains one functional open reading frame (ORF),
encoding the delta antigen [53]. This ORF is not encoded by
the genomic RNAbut by another RNA species that arises dur-
ing replication, the HDV antigenome, an exact complement
of the genome.
The delta antigen is translated from a third RNA species,
a linear 0.8 Kb messenger RNA (mRNA) of antigenomic
polarity and a 5󸀠-cap and 3󸀠-polyadenylated tail [54]. The
different HDV RNA species are represented in Figure 1. In an
infected cell, the three HDV RNA species accumulate in very
different amounts, although genomic RNA is the only species
assembled into HDV virions. HDV genomic RNA is themost














Figure 1: Schematic representation of three HDV RNA species.
The HDV genomic RNA is a single-stranded circular RNA with
∼1700 nucleotides. It forms an unbranched rod-like structure due
to intramolecular base pairing. The HDV antigenomic RNA is
the exact complement of the genomic RNA, and both RNAs have
site-specific ribozymes indicated by the black circle. The HDV
antigenomic RNA contains the open reading frame for the delta
antigen, represented in grey, but the antigen is translated from
another RNA species, the mRNA. The mRNA is ∼800 nucleotides
long with a 5󸀠-cap and a 3󸀠-polyadenylated tail.
cell whereas 100,000 copies of the antigenome are present
[53]. The HDV mRNA is considerably less abundant with
approximately 500 copies per cell [55].
Site-specific self-cleavage and ligation has been reported
on antigenomic HDVRNA, showing that this RNA possesses
ribozyme activity, just like plant viroids [56]. Both genomic
and antigenomic RNAs display this ribozyme activity, which
is comprised within a contiguous sequence of less than 100
nucleotides [57]. They enhance HDV RNA self-cleavage by
a 106- to 107-fold when compared with uncatalyzed cleavage
[58, 59]. Although ribozymes are characteristic of viroids,
their structures are different fromHDV ribozymes, which are
actually more related to the cytoplasmic polyadenylation
element-binding protein 3 (CPEB
3
) ribozyme, a conserved
mammalian sequence within an intron of the CPEB
3
gene
[60]. In fact, numerous HDV-like ribozymes have since been
found in several eukaryotic species [61].
6.3. HDV RNA Replication. HDV RNAs are transcribed in
the nucleus of infected cells, but the details of this process
remain poorly defined. The three RNA species that accu-
mulate in infected cells are the product of posttranscrip-
tional processing. The precursors, from which they arise, are
thought to be transcribed by a double-rolling circle mech-
anism, exemplified in Figure 2. In this model, the circular
genome RNA is used as a template to produce multimeric
species of opposite polarity [62]. These greater than unit-
length RNAs are subsequently self-cleaved by the HDV




























Figure 2: Model of HDV replication through a rolling-circle mechanism.The HDV genomic RNA is used as a template for the precursors of
HDV mRNA (Steps 1-2) and also acts as a template for multimeric RNAs of antigenomic polarity (Step 3). These multimeric RNAs contain
at least two copies of the HDV ribozyme and are thus self-cleaved to produce linear unit-length HDV antigenomes (Step 4), which are then
ligated to produce circular antigenomic RNA (Step 5). In turn, the new antigenomic RNA is a template for multimeric RNAs of genomic
polarity (Step 6) that are similarly self-cleaved and subsequently ligated to produce new circular genomic RNA (Steps 7-8).
ribozymes and religated, producing unit-length circular
antigenomic RNAs. The religation step is thought to involve
a host ligase [63] although it has been shown that the HDV
ribozyme can self-ligate in vitro [64]. Through a similar
mechanism, the unit-length circular antigenomic RNA acts
as a template for the transcription of multimeric species,
which are processed to produce genomic RNA.The genomic
RNA also acts as a template for transcripts that are processed
into mRNA.
Even though such a rolling-circle mechanism has been
widely accepted as a model for HDV replication, critical
details remain to be confirmed and/or clarified such as the
host cell components involved (reviewed by [65]).
HDV has no known DNA intermediate, as observed
for retroviruses [65], and the only HDV protein, the delta
antigen, is too small to be a polymerase.Thismeans thatHDV
RNA must somehow redirect host DNA-dependent RNA
polymerases to use HDV RNAs as templates. How this is
achieved and which host polymerase(s) is (are) involved have
been extensively studied but the results remain somewhat
controversial.
The host RNA polymerase II (pol II) seems to be
required for genomic HDV RNA transcription. Nuclear run-
on experiments on an endogenous HDV RNA template have
shown that inhibition of pol II by low concentrations of the
specific inhibitor 𝛼-amanitin blocks HDV RNA synthesis
of both the genomic and antigenomic strands [66]. One
possible explanation is that the rod-like conformation of
HDV RNAs may trick pol II into accepting the RNA as a
double-stranded DNA template. It has been shown, through
immunoprecipitation assays, that pol II binds the terminal
stem loop regions of HDV genome [67]. It has also been
reported that, after binding to the stem-loop, pol II is able to
elongate multimeric RNA species, carrying out transcription
[68]. Such elongation was observed on a partial antigenomic
RNA stem loop and originated a chimeric molecule of newly
synthesized transcript covalently bound to the 5󸀠-end of the
template.Thus, it is not clear if such elongation is biologically
relevant.
Despite being shown that pol II interacts with genomic
HDV RNA, it has been suggested that a different host
polymerase is responsible for the synthesis of antigenomic
HDV RNA [69, 70]. The idea that at least two different
host polymerases are involved in the HDV replication cycle
is based on the observation that, in transfected cells, the
synthesis of new HDV antigenomic RNA was not inhibited
by concentrations of 𝛼-amanitin that would inhibit pol II
activity [70]. This has led to the speculation that pol I copies
genomic HDV RNA to produce new antigenomic RNA [70].
This is contrary to the aforementioned nuclear run-on assays,
which have shown that both genomic and antigenomic RNA
syntheses are sensitive to low doses of 𝛼-amanitin, consistent
with pol II involvement [66]. Note that HDV RNA has been
detected in the nucleoplasm of cultured cells with nucleolus
exclusion [71]. This suggests that if another host polymerase,
other than pol II, is involved inHDVRNAreplication, it is pol
III, rather than pol I, which is resistant to high concentrations
of 𝛼-amanitin.
An additional complication arises from in vitro studies,
which indicate that fragments of the HDV RNA genome
interact not onlywith pol II but alsowith pol I and pol III [72].
However, such in vitro interactions may not have biological
relevance, especially since they do not lead to RNA-directed
transcription.
6 Advances in Virology
RBD CCD NLS 
1 12 60 66 75 97 146 
210 
S-HDAg 





Figure 3: Functional domains of S-HDAg and L-HDAg. The delta antigens share most of their sequence differing only in the 19-amino-
acid extension at the C-terminal of L-HDAg.They have, within the common sequence, as represented, a coiled-coil domain (CCD), a nuclear
localization signal (NLS), and an RNA binding domain (RBD). Also indicated on L-HDAg are the nuclear export signal (NES) and the unique
cysteine, residue 211, which is the target for farnesylation. The numbers indicate the position of the amino acid residues.
The HDV mRNA possesses characteristics of a pol II
transcript that is processed to a mRNA, namely, a 5󸀠-cap
structure and a 3󸀠-poly(A) tail. In fact, the role of pol II in
HDV mRNA transcription has been generally accepted [66,
69, 70, 73, 74].
The controversy regarding the transcription process is
thus limited to whether genomic RNA is transcribed by pol II
or another polymerase, either pol I or pol II [75]. If different
polymerases are involved, then distinct metabolic require-
ments, as well as accessory factors, are necessary to accom-
plish these processes (reviewed in [76]).
In addition to the posttranscriptional processing to make
the abovementioned three HDV RNAs, there is an important
RNA-editing event. During the virus replication cycle, some
of the antigenomes are edited at a specific site by a host
adenosine deaminase (ADAR1). This changes the adenosine
in the amber codon to inosine. After subsequent RNA-
directed RNA synthesis, it leads to the replacement of inosine
with guanosine [77]. That is, the UAG stop codon is changed
to a UGG tryptophan codon. In this way, the delta antigen
ORF is extended by 19 amino acids, that is, to the next stop
codon.The specificity of the editing site is in part directed by
the specific folding of the HDV antigenomic RNA [78].
Therefore, although HDV has only one ORF, it encodes
two proteins: the small delta antigen (S-HDAg) of 195 amino
acids and the large delta antigen (L-HDAg) with 214 amino
acids.
7. Delta Antigens
The two delta antigen isoforms share 195 amino acids and
differ only in that the large form has 19 extra amino acids on
the C-terminus. As such, S-HDAg and L-HDAg share sev-
eral functional domains within the common amino acid
sequence, as illustrated in Figure 3.The delta antigens contain
a nuclear localization signal (NLS) comprised by amino acids
66 through to 75 [79]; a coiled-coil domain (CCD), also
referred to as dimerization domain, within amino acids 12 to
60; and an RNA binding domain within amino acids 97 and
146 [80]. L-HDAg has, within its extra sequence, a nuclear
export signal (NES) spanning amino acids 198 to 210 [81].
Both delta antigens undergo posttranslational modifi-
cations (PTMs) by several host enzymes. Several groups
have investigated the impact these PTMs may have on the
antigens’ functions, but the precise significance of most of
these modifications remains uncertain.
The exception is one PTM, characteristic only of L-
HDAg, which has been shown to be essential. It occurs on
cysteine residue 211 and is mediated by a host farnesyltrans-
ferase [82, 83]. This isoprenylation of L-HDAg is necessary,
although not sufficient for viral packaging. It is somehow
necessary for the interactions with HBsAgs, leading to the
assembly of new viral particles [84, 85].
There are other PTM events, ones shared by both forms
of the delta antigen. These involve phosphorylation, methy-
lation, acetylation, and sumoylation (reviewed in [75]).
Phosphorylation has been observed at multiple sites,
mostly at serine and threonine residues. Different phosphor-
ylation patterns were observed for S-HDAg and L-HDAg,
and, if relevant, the distinct patterns may in part account
for their distinct biological functions [86]. Several host
enzymes have been reported to phosphorylate delta antigens
at different sites: casein kinase II on Ser2 and Ser213 [87];
double-stranded RNA-activated protein kinase R on residues
Ser177, Ser180, and Thr182 [88]; extracellular signal-related
kinases 1 and 2 (ERK1/2) on Ser177 [89]; and protein kinase
C on residue Ser210 [87]. It has been alleged that S-HDAg
phosphorylation increases replication of genomic HDVRNA
from the antigenomic strand [89]. By enhancing the expres-
sion of ERK1/2 in cells transfected with plasmids expressing
S-HDAg and dimeric HDV antigenomic RNA, an increase in
the accumulation of HDV genomic RNA was observed but
not for antigenomic RNA [89]. More recently, it has been
suggested that phosphorylation of S-HDAg at Ser177 can
work as a switch in HDV antigenomic RNA replication from
the initiation to the elongation stage [90].
Acetylation of Lys72 on S-HDAg, by host p300 acetyl-
transferase, is thought to regulate nucleocytoplasmic shut-
tling of viral RNA [91, 92]. Note that this amino acid is within
the NLS of the HDAgs [79]. Thus such a modification could
be expected to have an impact on nuclear import. Acetylation
of S-HDAg has also been suggested to function as a switch in
the synthesis of the different viral RNA species as this PTM
was reported to be essential for HDV genome and mRNA
synthesis but dispensable for antigenomic RNA synthesis
[93].
Methylation of Arg13 on S-HDAg, by protein arginine
methyltransferase I, has been observed in vitro and has also
been proposed to have a switching effect on HDVRNA repli-
cation [93, 94]. The studies were performed with S-HDAg
with anR13Amutation, which failed to bemethylated in vitro.
In transfected cells, the mutant S-HDAg reduced genomic
RNA synthesis and almost completely suppressed HDV
mRNA synthesis [93, 94].
Finally, SUMOylation of multiple lysine sites, by small
ubiquitin-related modifier isoform 1 (SUMO1), has been
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reported. Such PTM was detected on S-HDAg but not on L-
HDAg [95]. And this PTMwas proposed to enhance genomic
RNA and mRNA synthesis based on experiments where
SUMO1 was fused to S-HDAg, so as to mimic SUMOylated
S-HDAg [95].
Although the two delta antigens share sequence and
functional domains, they play very distinct roles in the HDV
replication cycle. S-HDAg is essential for HDV RNA accu-
mulation, whereas L-HDAg acts as a dominant negative
inhibitor of HDV replication [96] and also is essential for the
assembly, via HBsAgs, of HDV RNA into new virus particles.
There is, however, a common function attributed to both
antigens: it has been observed that both can downregulate
HBV replication in cultured cells [97].
Regarding the appearance of L-HDAg, it is important to
recall that because of the accumulated editing of the HDV
antigenome, the proportion of this form, in relation to the
total amount of accumulated HDAgs, increases during the
replication cycle from 0% to around 30%, [98]. This is suf-
ficient to suppress replication but allows the accumulation of
viral genomes that can then be packaged into new infectious
particles with the help of L-HDAg. The NES present in L-
HDAg allows the viral RNP to be exported from the nucleus
to the cytoplasm for packaging [81]. HDVRNPs then interact
with HBsAgs at the endoplasmatic reticulum to form new
infectious virions, which are then secreted to propagate
further rounds of HDV infection [71]. Such assembly of new
virions only occurs when HBsAgs are present; otherwise, the
viral RNPs return to the nucleus [71].
S-HDAg has beenmore thoroughly studied than the large
form, likely due to the fact that it is required for the accumu-
lation of HDVRNA. Several roles have been attributed to this
viral protein including putative and observed functions.
S-HDAg is present in the virions forming viral RNPs with
the HDV genome. One of the first tasks it performs is the
transport of the viral genome into the nucleus of infected
cells, where RNA-directed RNA synthesis takes place. This
transport is achieved by the presence of the previously
describedNLS andRBD.Nuclear importmay be facilitated by
karyopherin 2𝛼, since this importin interacts with S-HDAg in
vitro [99].
Another role attributed to S-HDAg is the regulation of
HDV RNA editing, particularly the deamination by ADAR-
1. This editing seems to occur at multiple locations on HDV
RNAs, but it is focused on the antigenomic RNA at the stop
codon adenosine [100]. S-HDAg has been found to suppress
editing at this stop codon when expressed in transfected cells
at levels close to those observed during HDV replication
[100]. This observation suggests that the antigen plays a role
in limiting HDV RNA editing, as excessive editing has been
shown to inhibit HDV RNA accumulation [101].
It has been known for more than two decades that the
small form of the delta antigen is essential for the accumu-
lation of processed HDV RNAs [96]. Several theories have
been proposed for the precise role(s) it may play, as will be
discussed ahead.
S-HDAg has been shown to interact with host pol II. In
a pull-down assay, both S-HDAg and L-HDAg fused with a
glutathione S-transferase tag were able to bind pol II from
HeLa nuclear extracts [102]. In the same study, S-HDAg was
observed to enhance pol II elongation, presumably by dis-
placing the subunit A of the negative elongation factor
(NELF-A). S-HDAg was thus reported as an elongation
enhancer of RNA-templated pol II transcription in vitro
[102]. However, the observed enhancement appears to be
limited to 3󸀠-OH end additions, rather than transcription. In
a subsequent study, Yamaguchi et al. reported that S-HDAg
functionally interacts with pol II suggesting that S-HDAg
may be involved in facilitating the uncommon RNA-directed
synthesis by an RNA polymerase that is normally DNA-
directed [103]. They proposed that the interaction between
pol II and S-HDAg loosens what, from molecular structure
studies, is considered to be a pol II clamp, thereby reducing
transcriptional fidelity and allowing the recognition of the
atypical RNA template.
Amidst all the reports that S-HDAg actively participates
in HDV RNA transcription, there is a contradictory result
showing that the presence of S-HDAg is not required for the
accumulation of processed short HDV transcripts, although
full-length transcripts, genomic or antigenomic, do require
S-HDAg, or even L-HDAg [104]. As an explanation, it was
proposed that full-length HDV RNAs are susceptible to
nucleolytic degradation in the absence of S-HDAg, and, due
to their size, such RNAs are more prone to be degraded than
smaller RNAs. In other words, S-HDAg interacts with HDV
RNAs to protect them and thereby allow their accumulation
in infected cells.
Another role attributed to S-HDAg is that of HDV
RNA chaperone. In vitro studies have reported that S-
HDAg can stimulate HDV RNA ribozyme activity [105].
From such studies, it is inferred that in vivo S-HDAg may
be directly involved in posttranscriptional processing of
nascent multimeric transcripts by enhancing cleavage into
unit-length molecules. It should be noted, however, that the
abovementioned studies of Lazinski and Taylor indicate that,
in vivo, HDAg is not directly needed for ribozyme cleavage
and subsequent ligation [104].
S-HDAg may also be involved in deviating/redirecting
other host cell components to facilitate HDV RNA replica-
tion. S-HDAg is a rather promiscuous protein in that many
cellular partners have been detected.
HDVhas a very small RNAgenome, asmentioned earlier,
and encodes only one viral protein,HDAg.Albeit the fact that
a second isoform of the HDAg appears later in the replication
cycle, S-HDAg and L-HDAg are not sufficient for HDV to
complete its replication cycle. HDV must rely extensively on
host cell factors to complete its replication cycle.
A comprehensive study using immunopurification fol-
lowed by mass spectrometry identified over 100 host proteins
associated with a tagged S-HDAg [105].This set included 9 of
the 12 subunits of the pol II complex, further supporting the
idea that pol II is involved in HDV RNA transcription [106].
In another study, a yeast two-hybrid approach identified
30 proteins encoded by a human liver cDNA library that
interacted with S-HDAg [107]. Only three proteins from this
study had also been identified by the previously mentioned
immunopurification approach.
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How can one small protein be involved in so many inter-
actions and perform such different functions? The answer
may be related to the S-HDAg’s lack of structure. Based on
S-HDAg’s sequence, it has been predicted that the protein
is extensively disordered [108]. The prediction that S-HDAg
is an intrinsically disordered protein (IDP) has been exper-
imentally confirmed by circular dichroism measurements,
which have shown that the protein has little structure apart
for its coiled-coil domain [108].
In fact, S-HDAg has several characteristics generally
attributed to IDPs.These proteins are commonly nucleic acid
binding proteins displaying chaperone activity, such as S-
HDAg. Also, a high net charge is characteristic and S-HDAg
has an estimated net charge of +12 [52]. Multimerization
ability is yet another feature of IDPs that is present in S-
HDAg.
The lack of a rigid 3-dimensional structure may account
for the protein’s promiscuity and ability to take part in several
interactions with distinct partners. As such, a deceivingly
simple virus, encoding only one protein, can hijack the host
cell mechanisms required to complete its life cycle.
8. Conclusion
More than 30 years after its discovery, a lot of fundamental
aspects of the HDV life cycle and interaction with the host
still remain unknown. But its peculiar simplicity makes all its
beauty.
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